Skip to Main content Skip to Navigation
Journal articles

Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma

Abstract : During the last few years, adoptive cellular therapy (ACT)-the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration-has been tested for treatment of melanoma tumours. Initial ACT used melanoma-infiltrating lymphocytes (TIL) that often contain tumour reactive lym-phocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Complete list of metadata

Cited literature [29 references]  Display  Hide  Download
Contributor : Nathalie LABARRIERE Connect in order to contact the contributor
Submitted on : Monday, February 17, 2020 - 6:00:30 PM
Last modification on : Wednesday, April 27, 2022 - 3:59:31 AM
Long-term archiving on: : Monday, May 18, 2020 - 6:24:32 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document


  • HAL Id : inserm-02482037, version 1


Nathalie Labarrière, Brigitte Dréno, Francine Jotereau. Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma. Current Cancer Therapy Reviews, Bentham Science Publishers, 2008, 4 (2), pp.125 - 129. ⟨inserm-02482037⟩



Record views